Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 5/20 | 0.74 |
| ▸ | CDC25B | P30305 | 5/20 | 0.50 |
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | SNCA | P37840 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.50 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.50 |
| ▸ | P4HB | P07237 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Bromo-1,4-Naphthoquinone SCHEMBL29633250 | 0.85 | PTPRC (0.68) | PTPRCCDC25BIDO1MAOAMAOB | |
| SCHEMBL6234343 | 0.85 | PTPRC (1.00) | PTPRCCDC25BMAOAMEN1KMT2A | |
| SCHEMBL30412470 | 0.85 | PTPRC (1.00) | PTPRCCDC25BMAOAMEN1KMT2A | |
| 2-Bromo-1,4-Naphthoquinone SCHEMBL312893 | 0.85 | PTPRC (0.68) | PTPRCCDC25BIDO1MAOAMAOB | |
| SCHEMBL9421518 | 0.80 | PTPRC (0.55) | PTPRCCDC25BIDO1MAOAMAOB | |
| SCHEMBL30098800 | 0.77 | PTPRC (0.57) | PTPRCCDC25BIDO1MAOAMAOB | |
| SCHEMBL30978710 | 0.73 | S100A4 (0.54) | PTPRCP4HBMAPK1CYP1A2S100A4 | |
| SCHEMBL9286666 | 0.72 | BACE1 (0.60) | PTPRCCDC25BIDO1MAOAMAOB | |
| SCHEMBL1708066 | 0.72 | BACE1 (0.60) | PTPRCCDC25BIDO1MAOAMAOB | |
| SCHEMBL15821387 | 0.70 | S100A4 (0.50) | PTPRCP4HBS100A4PTPN1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745117-A1 | NOVEL INDENONE DERIVATIVE AND USE THEREOF | Amyloid Solution Inc. (KR) | 2026-05-20 | — | — | EP | disclosed |
| US-8877747-B2 | Indenone derivative and pharmaceutical composition comprising same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2014-11-04 | — | — | US | disclosed |
| EP-2475649-B1 | INDENONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RES INST CHEM TECH (KR) | 2014-08-13 | — | — | EP | disclosed |
| US-20120214991-A1 | Indenone Derivative and Pharmaceutical Composition Comprising Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-23 | — | — | US | disclosed |
| EP-2475649-A1 | INDENONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Korea Research Institute Of Chemical Technology (KR) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011030955-A1 | INDENONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2011-03-17 | — | — | WO | disclosed |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-6903238-B2 | Substituted indenones as estrogenic agents | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030166643-A1 | Substituted indenones as estrogenic agents | WYETH | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166643-A1 | Substituted indenones as estrogenic agents | GPER1, ESR2, ESR1 | PTPRC 2859/4885CDC25B 2799/4885IDO1 1587/4885 |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | HTT, SNCA, PARK7 | PTPRC 4763/4885CDC25B 4802/4885IDO1 13/4885 |
| US-20120214991-A1 | Indenone Derivative and Pharmaceutical Composition Comprising Same | INSR, HSD17B7, SOST | PTPRC 3170/4885CDC25B 3279/4885IDO1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.